{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014866","form_type":"8-K","ticker":"SIGY","cik":"0001642159","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.387756+00:00","generated_at":"2026-06-03T22:16:30.599931+00:00","sec_items":["1.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sigyn Therapeutics converts $841k debentures to Series B Preferred; extends other debt to 2025","bullets":["Brio Capital converts $220,420 debentures into 292.4 shares of Series B Convertible Preferred Stock.","Osher Capital converts $621,000 debentures into 823.86 shares of Series B Convertible Preferred Stock.","Each Series B share is convertible into 125.63 common shares, subject to anti-dilution adjustments.","Brio and Osher amend additional debentures: maturity extended to March 31, 2025; principal increased to $125k and $316,350 respectively.","Additional automatic conversion of $1,856,566 aggregate debentures into Series B Preferred upon NASDAQ listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014866","json":"https://secwatch.observer/filing/0001493152-24-014866.json","markdown":"https://secwatch.observer/filing/0001493152-24-014866.md","text":"https://secwatch.observer/filing/0001493152-24-014866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642159/000149315224014866/0001493152-24-014866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642159/000149315224014866/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:16:30.599931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66362895f0c4bd4c9c6a414064f12776e76df26c","claim":"Sigyn Therapeutics, Inc. amended Debentures with Brio Capital Master Fund Ltd. and Osher Capital Partners, LLC valued at $110,000 and $275,000 (effective 2024-04-10).","evidence_excerpt":"Brio and Osher agreed to amend an additional $110,000 and $275,000, respectively, of Debentures to extend the maturity dates of such Debentures to March 31, 2025 in return for an increase in principal amount of such Debentures to $125,000 and $316,350","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315224014866/0001493152-24-014866-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Brio Capital Master Fund Ltd. and Osher Capital Partners, LLC"},{"label":"Value","value":"$110,000 and $275,000"},{"label":"Effective","value":"2024-04-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}